Latest Technology

Fully automated tablet & liquid manufacturing lines with HMI, PLC controlled interfaces and compliance with 21CFR 11.


Proposed New Plant being EU GMP Compliant

The State-of-the-Art manufacturing plant of Morison is compliant with the international standards which are defined by the EU GMP (Good Manufacturing Practice)that describe the minimum standard that  medicine manufacturers must meet in their production processes.

The European Medicines Agency (EMA) coordinates inspections to verify compliance with these standards and plays a key role in harmonizing GMP activities at European Union (EU) level. Plant with fully automated production Lines.

All machinery and processes are complying with 21CFR Part 11 of the The Code of Federal Regulations (CFR), the codification of the general and permanent rules and regulations (sometimes called administrative law) published in the Federal Register by the executive departments and agencies of the federal government of the United States. Title 21 of the Code of Federal Regulations that establishes the United States Food and Drug Administration (FDA) regulations on electronic records and electronic signatures (ERES). Part 11, as it is commonly called, defines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records.


Quality Systems & In house Compliance

Run by a qualified and experienced team of employees, our fully-fledged Chemical and Microbiology laboratory at Morison is capable of testing all required tests as per Pharmacopoeia which is governed by a robust quality process that ensures our manufacturing procedure and the manufactured solutions are of prime quality.

To further enhance the quality of our manufactured medications, we take special care in sourcing the raw materials through pre-approved suppliers that are being tested as per Pharmacopeia ( BP / USP/ IP ) complying with the requirements of pharmacopoeia.

Products

Pharma Therapeutic Classes

  • Analgesic/Non Steroid Anti- inflammatory Drug(NSAIDS)
  • Bronchodialator/Beta 2 –adrenoreceptor agonist
  • Glucocorticoid /immunosuppressant
  • Sulfonylurea/ Anti- Diabetic
  • Sedative Antihistamine/Histamine H1 Receptor Antagonist
  • Antiemetic, Dopermine receptor antagonist
  • Antacid and Antifatulent
  • Cephalosporin antibiotic
  • Vitamins and Minerals
  • Antiseptic Mouth Wash
  • Anti-diabetic/ Biguanide
  • Bronchodilator, Xanthines
  • Angiotensin II Receptor Antagonists.
  • Lipid Regulating Drug
  • Antiseptic
  • Imidazole Antibacterial
  • Analgesic/Anti pyretic
  • Topical Antiseptic
  • Bronchodilator Mucolytic
  • Non-Sedating Antihistamine/Histamine H1 Receptor Antagonist
  • Antifungal
  • Mild antacid, Anti fatulent
  • Vitamins
  • Calcium and Vitamin D supplement
  • Sedative Anti-histamine
  • Non Sedative Anti-histamine
  • Osmotic Laxative
  • Antacid/ Proton pump inhibitor
  • Anti-itchings, astringents, anti-inflammatory agents
  • Antacid with Local Anesthetic
  • Antibacterial
  • Antiasthmatic
  • Anti-inflammatory
  • Antihypertensive
  • Diuretic
  • Antibacterials

Existing Products

Buyback

The buyback is a signed agreement with Medical supplies division which signed and initiated on the year 2014 and at present, Morison PLC is one of the largest manufacturers in the Buyback Scheme.

Tender

SPC are open tenders which Supply to all the distribution channels of State Pharmaceuticals Corporation, and Morison PLC is one of the largest local suppliers in Tender Business in Sri Lanka as of present.

Innovative Molecules

Inhouse NPD

As a progressive company with a vision to address all health issues by providing accessible medical solutions, Morison’s in-house New Product Development (NPD) unit, continuously explores and experiments to deliver new product solutions aligned.

The NPD at Morison is responsible for the entire process of taking a product or service from concept to market, passing through a series of stages that new products typically go through, beginning with ideation, concept generation and ending with introducing the product to the market and to grow the market consistently.

Strategic Sourcing

Technological Partnership